Company intelligence / Profile preview

IDMI Pharmaceuticals

Irvine, California, United Statesidm-pharma.com ↗

Ownership: Private
Development stage: Other

Overview

IDM Pharma was a biopharmaceutical company focused on the development of innovative cancer immunotherapies. The company's lead product, Mepact (mifamurtide), was developed for the treatment of non-metastatic, resectable osteosarcoma and received marketing authorization in Europe. IDM Pharma utilized a proprietary platform to design molecules that stimulate the immune system to recognize and destroy cancer cells. The company was formed through the merger of IDM S.A. and Epimmune Inc. and was eventually acquired by Takeda Pharmaceutical Company in 2009.

Therapeutic areas: Oncology
Modalities: Cell therapyVaccineSmall moleculeMonoclonal antibody
Industry: Biotech

Partnerships

SanofiMedarex

Beyond the preview

Go deeper on IDMI Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IDMI Pharmaceuticals.

Explore the full profile